Therefore, studying the expression levels and activity of BCL2, BAX, and P53 in response to ZnO-PIP NPs treatment provides valuable insights into the underlying mechanisms of their anticancer effects and elucidates potential therapeutic targets for combating oral cancer. This evidence concerns the gene BAX and lip and oral cavity carcinoma.